FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000868983> ?p ?o ?g. }

• W2000868983 endingPage "1879" @default.
• W2000868983 startingPage "1871" @default.
• W2000868983 abstract "Accumulating evidence supports the idea that two known phosphatidylinositol 3'-kinase (PI3K) downstream proteins, Fra-1 and Survivin, are potential targets for cancer therapy. Increased expression of Fra-1, a Fos family member of the transcription factor activator protein-1, has been implicated in both the maintenance and the progression of the transformed state of several cancer cells. In addition, high Survivin expression in tumors correlates with more aggressive behavior, lower response to chemotherapeutic drugs, and shortened survival time. Previously, we reported that, in malignant mesothelioma cells with increased PI3K activity, small-molecule inhibitors of the PI3K/AKT pathway acted cooperatively with the amphibian RNase chemotherapeutic drug ranpirnase to inhibit cell growth. Because the thiazolidinedione antidiabetic drug rosiglitazone targets the PI3K/AKT pathway, we investigated the effect of the combination of these two drugs in cell survival in several cancer cell lines. We show here that the combination of ranpirnase and rosiglitazone synergistically decreases cell viability and increases cell apoptosis in several cancer cell lines. Cell killing is associated with decreased Fra-1 and Survivin expression and knockdown of Fra-1 increases cell killing by ranpirnase in a dose-dependent manner but not by rosiglitazone. The drug combination does not have a synergistic effect on killing in Fra-1 knockdown cells, showing that Fra-1 modulation accounts in part for the synergism. The novel drug combination of ranpirnase and rosiglitazone is a promising combination to treat cancers with increased PI3K-dependent Fra-1 expression or Survivin." @default.
• W2000868983 created "2016-06-24" @default.
• W2000868983 creator A5058577232 @default.
• W2000868983 creator A5077367312 @default.
• W2000868983 date "2008-07-01" @default.
• W2000868983 modified "2023-10-18" @default.
• W2000868983 title "A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells" @default.
• W2000868983 cites W1751235825 @default.
• W2000868983 cites W1873117454 @default.
• W2000868983 cites W1968853726 @default.
• W2000868983 cites W1969741427 @default.
• W2000868983 cites W1984719034 @default.
• W2000868983 cites W2010325864 @default.
• W2000868983 cites W2023572101 @default.
• W2000868983 cites W2034387261 @default.
• W2000868983 cites W2035523654 @default.
• W2000868983 cites W2042904167 @default.
• W2000868983 cites W2063563750 @default.
• W2000868983 cites W2067337949 @default.
• W2000868983 cites W2067837009 @default.
• W2000868983 cites W2073693436 @default.
• W2000868983 cites W2108158680 @default.
• W2000868983 cites W2108332294 @default.
• W2000868983 cites W2116917178 @default.
• W2000868983 cites W2126029539 @default.
• W2000868983 cites W2135924782 @default.
• W2000868983 cites W2136136285 @default.
• W2000868983 cites W2155148117 @default.
• W2000868983 cites W2321900095 @default.
• W2000868983 cites W2388163742 @default.
• W2000868983 doi "https://doi.org/10.1158/1535-7163.mct-08-0308" @default.
• W2000868983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2574777" @default.
• W2000868983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18606715" @default.
• W2000868983 hasPublicationYear "2008" @default.
• W2000868983 type Work @default.
• W2000868983 sameAs 2000868983 @default.
• W2000868983 citedByCount "17" @default.
• W2000868983 countsByYear W20008689832012 @default.
• W2000868983 countsByYear W20008689832013 @default.
• W2000868983 countsByYear W20008689832014 @default.
• W2000868983 countsByYear W20008689832015 @default.
• W2000868983 countsByYear W20008689832017 @default.
• W2000868983 countsByYear W20008689832020 @default.
• W2000868983 countsByYear W20008689832022 @default.
• W2000868983 countsByYear W20008689832023 @default.
• W2000868983 crossrefType "journal-article" @default.
• W2000868983 hasAuthorship W2000868983A5058577232 @default.
• W2000868983 hasAuthorship W2000868983A5077367312 @default.
• W2000868983 hasBestOaLocation W20008689831 @default.
• W2000868983 hasConcept C121608353 @default.
• W2000868983 hasConcept C126322002 @default.
• W2000868983 hasConcept C170493617 @default.
• W2000868983 hasConcept C173396325 @default.
• W2000868983 hasConcept C185592680 @default.
• W2000868983 hasConcept C190283241 @default.
• W2000868983 hasConcept C2775975398 @default.
• W2000868983 hasConcept C2780152017 @default.
• W2000868983 hasConcept C502942594 @default.
• W2000868983 hasConcept C53227056 @default.
• W2000868983 hasConcept C55493867 @default.
• W2000868983 hasConcept C62112901 @default.
• W2000868983 hasConcept C71924100 @default.
• W2000868983 hasConcept C75217442 @default.
• W2000868983 hasConcept C86554907 @default.
• W2000868983 hasConcept C86803240 @default.
• W2000868983 hasConcept C96232424 @default.
• W2000868983 hasConcept C98274493 @default.
• W2000868983 hasConceptScore W2000868983C121608353 @default.
• W2000868983 hasConceptScore W2000868983C126322002 @default.
• W2000868983 hasConceptScore W2000868983C170493617 @default.
• W2000868983 hasConceptScore W2000868983C173396325 @default.
• W2000868983 hasConceptScore W2000868983C185592680 @default.
• W2000868983 hasConceptScore W2000868983C190283241 @default.
• W2000868983 hasConceptScore W2000868983C2775975398 @default.
• W2000868983 hasConceptScore W2000868983C2780152017 @default.
• W2000868983 hasConceptScore W2000868983C502942594 @default.
• W2000868983 hasConceptScore W2000868983C53227056 @default.
• W2000868983 hasConceptScore W2000868983C55493867 @default.
• W2000868983 hasConceptScore W2000868983C62112901 @default.
• W2000868983 hasConceptScore W2000868983C71924100 @default.
• W2000868983 hasConceptScore W2000868983C75217442 @default.
• W2000868983 hasConceptScore W2000868983C86554907 @default.
• W2000868983 hasConceptScore W2000868983C86803240 @default.
• W2000868983 hasConceptScore W2000868983C96232424 @default.
• W2000868983 hasConceptScore W2000868983C98274493 @default.
• W2000868983 hasIssue "7" @default.
• W2000868983 hasLocation W20008689831 @default.
• W2000868983 hasLocation W20008689832 @default.
• W2000868983 hasLocation W20008689833 @default.
• W2000868983 hasLocation W20008689834 @default.
• W2000868983 hasOpenAccess W2000868983 @default.
• W2000868983 hasPrimaryLocation W20008689831 @default.
• W2000868983 hasRelatedWork W1989444090 @default.
• W2000868983 hasRelatedWork W2022070430 @default.
• W2000868983 hasRelatedWork W2026216334 @default.
• W2000868983 hasRelatedWork W2075754577 @default.
• W2000868983 hasRelatedWork W2101142723 @default.
• W2000868983 hasRelatedWork W2385169010 @default.

• next